Southeast Asia Insulins Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Insulins Market Overview

The Southeast Asia insulins market was valued at USD 292.42 Million in 2025 and is projected to reach USD 240.00 Million by 2033, growing at a CAGR of 2.50% from 2026 to 2033. Market growth is driven by the rising prevalence of diabetes, increasing demand for effective blood glucose management, and the growing adoption of insulin analogues for improved glycemic control. The market is further supported by advancements in insulin delivery systems, including insulin pens, pumps, and other patient-friendly administration technologies. Additionally, the increasing focus on personalized diabetes treatment, expanding healthcare access, and the availability of different insulin formulations, including rapid-acting, short-acting, intermediate-acting, long-acting, and premixed insulin, are supporting market development. However, pricing pressures, reimbursement challenges, and the availability of alternative diabetes treatments may influence market growth during the forecast period.

Market Size & Forecast

• Southeast Asia Market Value (2025): USD 292.42 Million
• Expected Market Value (2033): USD 240.00 Million
• Forecast CAGR (2026–2033): 2.50%
• Leading Country in 2025: Indonesia
• Fastest Growing Country: Indonesia

Key Market Trends & Insights

• Indonesia dominated the Southeast Asia insulins market, accounting for the largest revenue share of 52.92% in 2025, supported by the country's large population of people living with diabetes, expanding public healthcare initiatives, and established insulin distribution networks. Government programs aimed at improving access to essential medicines, including insulin, are supporting treatment availability across public healthcare facilities.
• The insulin aspart segment dominated the Southeast Asia insulins market, accounting for a revenue share of 27.20% in 2025, driven by its widespread use as a long-acting basal insulin for managing Type 1 and Type 2 diabetes. Its ability to provide sustained blood glucose control between meals and overnight supports effective long-term diabetes management.
• Indonesia is expected to be the fastest-growing country in the Southeast Asia insulins market, registering a CAGR of 2.50% during 2026–2033. Growth is supported by the rising demand for effective diabetes management, continued adoption of insulin therapies, and advancements in insulin delivery technologies. Established healthcare infrastructure and access to modern treatment options are also expected to support market expansion.
• The analogue segment dominated the Southeast Asia insulins market, accounting for a revenue share of 83.10% in 2025, driven by the increasing adoption of advanced insulin therapies for effective blood glucose management. Insulin analogues offer flexible dosing schedules and more predictable glucose control, supporting their use among patients with Type 1 and Type 2 diabetes.
• The basal segment dominated the Southeast Asia insulins market, accounting for a revenue share of 54.11% in 2025, supported by its essential role in maintaining stable blood glucose levels between meals and overnight. Basal insulin is widely used in the long-term management of Type 1 and Type 2 diabetes, contributing to consistent demand across the country.
• The reusable-pen cartridge segment dominated the Southeast Asia insulins market, accounting for a revenue share of 59.90% in 2025, driven by its convenience, dosing accuracy, and suitability for long-term diabetes management. Reusable insulin pens allow patients to replace empty cartridges without discarding the entire device, offering a practical and cost-effective option for regular insulin administration.

Report Scope and Insulins Market Segmentation      

Insulins Market Trends

Trend: Advancements in Insulin Formulations and Delivery Technologies

The Southeast Asia insulins market is increasingly characterized by advancements in insulin formulations, improvements in drug delivery technologies, and efforts to enhance treatment convenience and blood glucose management. Manufacturers are focusing on developing rapid-acting, long-acting, and ultra-long-acting insulin formulations to address the diverse treatment requirements of patients with Type 1 and Type 2 diabetes. The growing adoption of insulin analogues is supporting this trend because these formulations can provide more predictable glucose control and greater flexibility in dosing. In addition, technological advancements in insulin pens, insulin pumps, and automated insulin delivery systems are improving administration convenience and supporting personalized diabetes management. Manufacturers are also investing in biomanufacturing process optimization to improve production efficiency, maintain product quality, and strengthen insulin supply. Furthermore, increasing demand for affordable insulin products and the expansion of biosimilar and follow-on insulin options are encouraging competition and supporting broader access to diabetes treatments.

For instance,

• On September 24, 2026, Eli Lilly and Company announced that the U.S. FDA had approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with Type 2 diabetes. The formulation is designed to reduce injection frequency compared with daily basal insulin, highlighting advancements in insulin formulations aimed at improving treatment convenience and supporting long-term diabetes management.
• On July 9, 2026, Novo Nordisk launched Awiqli (insulin icodec) in India. The once-weekly basal insulin offers an alternative to daily injections, reducing the number of scheduled injections from 365 to 52 per year. The launch highlights the development of longer-acting insulin formulations designed to simplify treatment routines and potentially reduce barriers to insulin initiation.
• On February 14, 2025, the U.S. FDA approved Merilog (insulin aspart-szjj), developed by Sanofi, as a biosimilar to NovoLog for improving blood glucose control in adults and children with diabetes. The product was approved in prefilled-pen and multiple-dose vial presentations. This development highlights growing competition in the insulin market and efforts to expand treatment options through biosimilar insulin products.

Overall, these developments highlight the growing importance of formulation innovation, advanced delivery systems, and manufacturing efficiency in the Southeast Asia insulins market. Increasing demand for effective long-term diabetes management, greater emphasis on patient convenience, and the need to improve access to affordable insulin therapies are encouraging manufacturers to invest in product development and technological improvements. Continued innovation in insulin analogues, delivery devices, and biomanufacturing processes is expected to shape competitive strategies and support the evolution of the Southeast Asia insulins market during the forecast period.

Southeast Asia Insulins Market Dynamics

Key Market Driver: Expanding Insulin Portfolios and Advancements in Biomanufacturing

The Southeast Asia insulins market is driven by the continuous expansion of insulin product portfolios and advancements in biomanufacturing technologies that improve production efficiency, product quality, and treatment accessibility. Manufacturers are developing and commercializing different insulin formulations, including rapid-acting, short-acting, intermediate-acting, long-acting, and premixed insulins, to address the diverse treatment requirements of patients with Type 1 and Type 2 diabetes. Advancements in recombinant DNA technology, cell-line development, fermentation, purification, and process optimization are supporting consistent insulin production and improved manufacturing scalability. Furthermore, the development of insulin analogues and biosimilar insulin products is creating opportunities to improve glycemic control and expand access to more affordable treatment options. Increasing demand for diabetes care, growing investments in manufacturing capacity, and strategic collaborations among pharmaceutical companies are further encouraging innovation and strengthening the Southeast Asia insulin supply chain.

For instance,

• In March 2025, the U.S. Food and Drug Administration approved Kirsty (insulin aspart-xjhz), developed by Biocon Biologics, as a biosimilar to NovoLog, expanding the availability of insulin treatment options in the U.S. market.
• In July 2025, Biocon Biologics announced the U.S. launch of Kirsty, strengthening its commercial insulin portfolio and expanding access to an affordable rapid-acting insulin option for diabetes management.
• In January 2026, the Southeast Asiaan Commission approved Ondibta (insulin glargine), developed by Gan & Lee Pharmaceuticals and commercialized in Southeast Asia by Sandoz, expanding the availability of biosimilar basal insulin for patients requiring long-acting insulin therapy.

Overall, expanding insulin portfolios and advancements in biomanufacturing are supporting the development of more diverse, scalable, and cost-effective insulin therapies. Improvements in production technologies, the introduction of biosimilar insulin products, and investments in manufacturing capacity are helping manufacturers address the growing demand for diabetes treatment. These developments are expected to support product availability, strengthen competition, and contribute to the growth of the Southeast Asia insulins market during the forecast period.

Key Restraint/Challenge: High Manufacturing Complexity and Stringent Quality Requirements

The Southeast Asia insulins market faces challenges associated with the complexity of manufacturing insulin products, maintaining consistent product quality, and complying with stringent regulatory requirements. Insulin is a highly sensitive biological medicine that requires precise control over fermentation, purification, formulation, and storage conditions to maintain its potency, stability, and safety. Manufacturers must invest significantly in specialized production facilities, advanced analytical testing, and quality-control systems to ensure batch-to-batch consistency. Furthermore, maintaining the cold chain throughout transportation and distribution increases operational costs and creates additional challenges in countrys with limited healthcare infrastructure. Price-control policies, reimbursement limitations, and competition from established manufacturers can also restrict profit margins and discourage investment in production capacity. These factors may delay product launches, limit affordability, and create supply constraints, particularly in low- and middle-income countries.

For instance,

• In March 2026, a stolen consignment of Lantus SoloStar insulin in India prompted a safety alert, highlighting the importance of secure pharmaceutical transportation, product traceability, and cold-chain integrity.
• In April 2026, India considered revising storage regulations for vaccines and biological products, including insulin, highlighting the need for stricter handling standards and reliable temperature-controlled distribution networks.
• In April 2026, Biocon Biologics highlighted potential capacity constraints in insulin cartridges and pens as some pharmaceutical companies shifted their focus toward GLP-1 therapies, raising concerns about continued investment in insulin manufacturing and supply.

Overall, manufacturing complexity, cold-chain requirements, regulatory compliance, and pricing pressure remain significant challenges for the Southeast Asia insulins market. Addressing these barriers requires investment in efficient biomanufacturing technologies, reliable distribution networks, robust quality-control systems, and cost-effective production processes. Improvements in manufacturing efficiency and supply-chain resilience will be essential to maintaining consistent insulin availability and supporting broader access to diabetes treatment during the forecast period.

Key Market Opportunity: Advancements in Insulin Formulations and Expansion of Affordable Diabetes Care

The Southeast Asia insulins market presents significant growth opportunities through the development of advanced insulin formulations, expansion of affordable treatment options, and improvements in insulin manufacturing technologies. The rising prevalence of Type 1 and Type 2 diabetes is increasing the need for effective and convenient blood glucose management solutions. Manufacturers are focusing on developing rapid-acting and long-acting insulin analogues, concentrated insulin formulations, and products compatible with insulin pens and pumps to improve treatment flexibility and patient adherence. Furthermore, advancements in recombinant DNA technology, cell culture processes, purification methods, and large-scale biomanufacturing are creating opportunities to improve production efficiency and strengthen supply reliability. The growing demand for affordable insulin, particularly in emerging economies, is also encouraging manufacturers to expand production capacity and distribution networks. In addition, collaborations between pharmaceutical companies, healthcare providers, and public health organizations are creating opportunities to improve insulin availability and expand access to diabetes care.

For instance,

• In July 2025, Biocon Biologics received U.S. FDA approval for Kirsty (insulin aspart), a rapid-acting insulin product, expanding its insulin portfolio and creating opportunities to improve access to insulin therapy.
• In October 2025, Biocon Biologics and Civica announced a collaboration related to insulin glargine supply, reflecting efforts to improve the availability of affordable insulin in the U.S. market.
• In January 2026, California's CalRx initiative made insulin glargine available through its affordability program, highlighting opportunities to expand access to lower-cost insulin products and address affordability challenges.

Overall, the expansion of insulin portfolios, advances in biomanufacturing, and growing emphasis on affordable diabetes treatment are expected to create new opportunities in the Southeast Asia insulins market. Continued innovation in insulin formulations, investments in manufacturing capacity, and strategic collaborations are likely to improve product availability and support market development during the forecast period.

Southeast Asia Insulins Market Scope

The Southeast Asia insulin market is segmented into five notable segments based on molecule, insulin class, therapeutic category, presentation / device, channel.

• By molecule

On the basis of molecule, the Southeast Asia insulin market is segmented into human insulin, insulin aspart, insulin glargine, insulin lispro, insulin degludec, insulin degludec; insulin aspart, insulin degludec; liraglutide, insulin detemir, insulin glargine; lixisenatide, insulin glulisine, insulin icodec, and insulin icodec; semaglutide. In 2025, the insulin glargine segment is expected to dominate the Southeast Asia insulins market with a market share of 27.20%, due to its widespread use in managing Type 1 and Type 2 diabetes through long-acting basal insulin therapy. Insulin glargine provides sustained blood glucose control over an extended period, helping maintain stable glucose levels between meals and overnight.

The insulin icodec segment is projected to register the fastest CAGR of 8.85% from 2026 to 2033, owing to the growing demand for advanced diabetes management therapies, increasing interest in long-acting treatment options, and the need to improve patient adherence to treatment.

• By insulin class

On the basis of insulin class, the Southeast Asia insulin market is segmented into human insulin and analogue. In 2025, the analogue segment is expected to dominate the Southeast Asia insulins market with a market share of 83.10%, due to its ability to provide more predictable blood glucose control, flexible dosing schedules, and improved treatment management for patients with Type 1 and Type 2 diabetes. Insulin analogues, including rapid-acting and long-acting formulations, are designed to mimic the body's natural insulin response more closely than conventional human insulin.

The analogue segment is projected to register the fastest CAGR of 3.58% from 2026 to 2033, owing to the increasing prevalence of diabetes, rising demand for advanced insulin therapies, and the growing preference for flexible and effective blood glucose management.

• By therapeutic category

On the basis of therapeutic category, the Southeast Asia insulin market is segmented into basal, prandial, premix, and fixed combination with GLP-1. In 2025, the basal segment is expected to dominate the Southeast Asia insulins market with a market share of 54.11%, due to its essential role in maintaining stable blood glucose levels between meals and during overnight fasting. Basal insulin provides sustained glucose control over an extended period and is widely used in the long-term management of Type 1 and Type 2 diabetes.

The fixed combination with GLP-1 segment is projected to register the fastest CAGR of 7.47% from 2026 to 2033, owing to the increasing demand for integrated diabetes management therapies that combine basal insulin with glucagon-like peptide-1 (GLP-1) receptor agonists. These combination treatments help improve blood glucose control through complementary mechanisms, as insulin regulates glucose levels while GLP-1 receptor agonists support glucose-dependent insulin secretion, suppress glucagon release, and may promote weight loss.

• By presentation / device

On the basis of presentation / device, the Southeast Asia insulin market is segmented into vial, cartridge, reusable-pen cartridge, disposable pen, and legs/other. In 2025, the disposable pen segment is expected to dominate the Southeast Asia insulins market with a market share of 59.90%, due to its convenience, dosing accuracy, and suitability for long-term diabetes management. Reusable insulin pens allow patients to replace empty cartridges without discarding the entire device, making them a practical option for individuals requiring regular insulin administration.

The disposable pen segment is projected to register the fastest CAGR of 5.03% from 2026 to 2033, owing to the increasing demand for convenient, user-friendly, and ready-to-use insulin delivery devices. Disposable insulin pens eliminate the need for cartridge replacement and device maintenance, making them suitable for patients seeking simple and efficient diabetes management solutions.

• By channel

On the basis of channel, the Southeast Asia insulin market is segmented into public tender, hospital, retail pharmacy, and private market. In 2025, the retail pharmacy segment is expected to dominate the Southeast Asia insulins market with a market share of 40.00%, due to the widespread availability of insulin products through community pharmacies and established pharmaceutical distribution networks. Retail pharmacies provide convenient access to insulin formulations, including human insulin and insulin analogues, enabling patients with Type 1 and Type 2 diabetes to obtain prescribed treatments for ongoing disease management.

The public tender segment is projected to register the fastest CAGR of 4.18% from 2026 to 2033, owing to increasing government initiatives to improve access to affordable insulin therapies and strengthen diabetes care through public healthcare systems.

Southeast Asia Insulins Market Countryal Analysis

Indonesia dominated the Southeast Asia insulins market and accounted for the largest revenue share of 52.92% in 2025, driven by the well-established healthcare infrastructure, widespread access to diabetes diagnosis and treatment, and strong adoption of advanced insulin therapies across the country. The rising prevalence of diabetes, favorable reimbursement policies, and the availability of human insulin and insulin analogues are supporting market demand. Furthermore, the presence of established pharmaceutical manufacturers, increasing adoption of insulin pens and other advanced delivery devices, and government initiatives to improve diabetes management are contributing to countryal market growth.

Moreover, the Indonesia is projected to register the highest CAGR of 2.50% during 2026–2033, driven by the increasing prevalence of diabetes, growing demand for advanced insulin formulations, and continued improvements in diabetes care across the country. Established healthcare infrastructure, favorable reimbursement policies, and widespread access to insulin analogues are expected to support market expansion. Furthermore, increasing adoption of insulin pens and other convenient drug delivery systems, along with ongoing efforts to improve treatment adherence and glycemic control, is expected to contribute to the growth of the Southeast Asiaan insulins market during the forecast period.

Indonesia Insulins Market Insight

The Indonesia insulins market is driven by the rising prevalence of diabetes, increasing awareness of blood glucose management, and growing demand for accessible insulin therapies. Government initiatives through the national healthcare system are supporting access to diabetes treatment, including insulin, across public healthcare facilities. Furthermore, improvements in healthcare infrastructure, expanding pharmaceutical distribution networks, and increasing adoption of insulin analogues are contributing to market development. However, affordability constraints, uneven access to specialized healthcare services, and challenges in maintaining insulin storage and distribution conditions across the archipelago may influence market expansion during the forecast period.

Thailand Insulins Market Insight

The Thailand insulins market is supported by the rising prevalence of diabetes, increasing demand for effective blood glucose management, and expanding access to healthcare services. Government initiatives aimed at improving access to essential medicines through public healthcare coverage are supporting insulin availability among patients requiring long-term treatment. Furthermore, growing awareness of diabetes complications, increasing adoption of insulin analogues, and improvements in diabetes diagnosis are contributing to market development. However, affordability concerns, differences in healthcare access between urban and rural areas, and the cost of advanced insulin delivery devices may influence market growth during the forecast period.

Vietnam Insulins Market Insight

The Vietnam insulins market is supported by the rising prevalence of diabetes, increasing awareness of blood glucose management, and growing demand for accessible diabetes treatments. Improvements in healthcare infrastructure and expanding access to diagnostic services are encouraging more patients to seek appropriate insulin therapy. Furthermore, government initiatives to strengthen chronic disease management, increasing availability of human insulin and insulin analogues, and the expansion of pharmaceutical distribution networks are supporting market development. However, affordability concerns, disparities in healthcare access between urban and rural areas, and dependence on imported insulin products may influence market growth during the forecast period.

Southeast Asia Insulins Market Share

The Southeast Asia insulins industry is primarily led by well-established companies, including:

• Biocon Biologics (India)
• Biomm (Germany)
• Eli Lilly and Company (U.S.)
• Gan & Lee Pharmaceuticals (China)
• Julphar (U.A.E.)
• Novo Nordisk (Denmark)
• Sanofi (France)
• Sedico Pharmaceutical Company (Egypt)
• Tonghua Dongbao Pharmaceutical (China)
• Wockhardt (India)

Latest Developments in Southeast Asia Insulins Market

• In July 2025, The U.S. FDA approved Kirsty (insulin aspart-xjhz), a rapid-acting biosimilar insulin, as an interchangeable biosimilar to NovoLog. The product is available in prefilled pen and vial presentations, expanding Biocon Biologics' insulin portfolio and increasing competition in the rapid-acting insulin segment.
• In October 2025, Biocon Biologics and Civica expanded their collaboration to include insulin glargine under a private-label arrangement. Biocon supplies the insulin, while Civica commercializes it under its own label. The agreement aims to increase the availability of affordable insulin and strengthen competition in the U.S. market.
• In Janaury 2026, California introduced CalRx-branded biosimilar insulin glargine pens through its partnership with Civica and Biocon Biologics. The announced price was no more than USD 55 for a five-pack of pens. The initiative represents a public-sector approach to improving insulin affordability and increasing price competition.
• In May 2026, Sandoz confirmed Southeast Asiaan Commission marketing authorization for Ondibta, a biosimilar insulin glargine developed and registered by Gan & Lee Pharmaceuticals. The medicine was approved for diabetes treatment across the reference product's indications, with a launch expected by early 2027. The approval may broaden treatment choice and intensify competition in Southeast Asia's basal insulin market.
• In June 2026, Biocon announced that its long-standing partner Duopharma Biotech secured multiple Malaysian Ministry of Health contracts valued at more than MYR 225 million. Biocon will supply human insulin, insulin glargine, and insulin aspart for distribution under the contracts. The agreements reinforce public-sector procurement and support continuity of insulin supply in Southeast Asia.